Story details

   Live Viewers: 47      Total Pageviews: 93

Trial Shows Engineered T-Cells Act on Multiple Myeloma | Science and Enterprise

An early-stage clinical trial shows immune system cells from patients with the blood-related cancer multiple myeloma — modified to attack a protein suspected of helping the cancer grow — generated a positive clinical response in most of the participants, without the serious adverse effects usually encountered in immunotherapies,

Submit a Comment (Logged In Users)

Log in to comment or register here

Don't Miss the Next Big Thing.

Stay Updated with Awesome Science Stuffs.